^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

IDH1 R132

i
Other names: HEL-216, HEL-S-26, Epididymis Luminal Protein 216, Isocitrate Dehydrogenase 1 (NADP+), Epididymis Secretory Protein Li 26, IDH1, Isocitrate Dehydrogenase (NADP(+)) 1, Isocitrate Dehydrogenase 1 (NADP+), Soluble
Entrez ID:
Related biomarkers:
Phase 4
GT Medical Technologies, Inc.
Recruiting
Last update posted :
05/15/2024
Initiation :
08/17/2022
Primary completion :
07/01/2027
Completion :
12/01/2027
IDH1
|
IDH1 R132H • IDH wild-type • IDH1 R132
|
temozolomide
Phase 1
Institut de Recherches Internationales Servier
Recruiting
Last update posted :
05/08/2024
Initiation :
01/20/2023
Primary completion :
02/28/2025
Completion :
08/30/2027
IDH1 • ATRX
|
ATRX mutation • IDH1 R132H • IDH1 R132
|
Keytruda (pembrolizumab) • vorasidenib (S95032)
Phase 1/2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
05/02/2024
Initiation :
03/19/2018
Primary completion :
09/30/2025
Completion :
09/30/2025
IDH1
|
IDH1 R132
|
Venclexta (venetoclax) • azacitidine • Tibsovo (ivosidenib)
Phase 2/3
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
05/01/2024
Initiation :
09/01/2020
Primary completion :
04/13/2023
Completion :
03/11/2025
PD-L1 • TMB • IDH1 • MGMT
|
PD-L1 expression • MGMT promoter methylation • IDH1 R132H • IDH1 R132 • MGMT expression
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • temozolomide • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)
Phase 1
Bayer
Active, not recruiting
Last update posted :
04/30/2024
Initiation :
05/26/2016
Primary completion :
11/08/2018
Completion :
12/31/2024
IDH1
|
IDH1 mutation • IDH1 R132
|
BAY1436032
Phase 3
CarThera
Recruiting
Last update posted :
04/24/2024
Initiation :
01/29/2024
Primary completion :
01/28/2028
Completion :
06/30/2028
BRAF • IDH1
|
BRAF mutation • IDH1 R132H • IDH1 R132
|
carboplatin • temozolomide • lomustine
Phase 1/2
Forma Therapeutics, Inc.
Completed
Last update posted :
04/10/2024
Initiation :
04/01/2016
Primary completion :
12/28/2023
Completion :
01/24/2024
IDH1
|
IDH1 R132 • Chr t(15;17)
|
cytarabine • azacitidine • Rezlidhia (olutasidenib)
Phase 1/2
Servier Bio-Innovation LLC
Recruiting
Last update posted :
04/09/2024
Initiation :
10/23/2023
Primary completion :
03/01/2026
Completion :
03/01/2026
IDH1
|
IDH1 R132C • IDH1 R132
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Tibsovo (ivosidenib)
Phase 1
Institut de Recherches Internationales Servier
Recruiting
Last update posted :
04/05/2024
Initiation :
03/01/2014
Primary completion :
02/01/2025
Completion :
08/01/2025
IDH1
|
IDH1 R132
|
Tibsovo (ivosidenib)
Phase 2
Assistance Publique - Hôpitaux de Paris
Completed
Last update posted :
04/02/2024
Initiation :
07/30/2019
Primary completion :
12/02/2020
Completion :
08/18/2021
PD-L1 • TMB • IDH1 • IDH2 • MGMT • CD8 • PD-1 • ATRX • CD163 • CD4 • CD68 • FOXP3 • GFAP • OLIG2
|
IDH1 mutation • IDH2 mutation • IDH1 R132H • IDH1 R132
|
Opdivo (nivolumab) • temozolomide
Phase 1
Katy Peters, MD, PhD
Not yet recruiting
Last update posted :
03/21/2024
Initiation :
06/01/2024
Primary completion :
08/01/2025
Completion :
08/01/2027
IDH1
|
IDH1 mutation • IDH1 R132
|
vorasidenib (S95032)
Phase 2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
03/15/2024
Initiation :
12/30/2020
Primary completion :
06/01/2025
Completion :
06/01/2025
IDH1
|
IDH1 R132
|
Tibsovo (ivosidenib) • Vyxeos (cytarabine/daunorubicin liposomal formulation)
Phase N/A
Daiichi Sankyo
Active, not recruiting
Last update posted :
03/15/2024
Initiation :
01/19/2017
Primary completion :
01/31/2021
Completion :
03/01/2026
IDH1
|
IDH1 R132
|
safusidenib (AB-218)
Phase 1
Massachusetts General Hospital
Completed
Last update posted :
03/08/2024
Initiation :
01/16/2019
Primary completion :
05/22/2022
Completion :
06/06/2023
IDH1 • HLA-B
|
IDH1 mutation • IDH1 R132
|
Tibsovo (ivosidenib)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
03/06/2024
Initiation :
01/30/2019
Primary completion :
07/31/2024
Completion :
07/31/2024
IDH1 • IDH2
|
IDH2 mutation • IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH1 R132 • IDH1 R132G • IDH2 R140Q • IDH1 R132L • IDH1 R132S • IDH1 R132V • IDH2 R172 • IDH2 R172G
|
Lynparza (olaparib)
Phase 3
Servier Affaires Médicales
Recruiting
Last update posted :
03/05/2024
Initiation :
05/03/2023
Primary completion :
06/01/2025
Completion :
06/01/2025
IDH1
|
IDH1 R132H • IDH1 R132C • IDH1 R132 • IDH1 R132G • IDH1 R132L • IDH1 R132S
|
Tibsovo (ivosidenib)
Phase 1
Institut de Recherches Internationales Servier
Active, not recruiting
Last update posted :
02/26/2024
Initiation :
03/20/2018
Primary completion :
08/02/2019
Completion :
05/01/2025
IDH1 • ATRX
|
ATRX mutation • IDH1 R132H • IDH1 R132
|
Tibsovo (ivosidenib) • vorasidenib (S95032)
Phase 1
Hutchmed
Recruiting
Last update posted :
02/14/2024
Initiation :
02/28/2021
Primary completion :
09/30/2024
Completion :
06/30/2025
IDH1 • IDH2
|
IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH1 R132 • IDH2 R140Q • IDH2 R172
|
HMPL-306
Phase 1
Istituto Oncologico Veneto IRCCS
Recruiting
Last update posted :
02/12/2024
Initiation :
07/04/2022
Primary completion :
12/01/2024
Completion :
12/01/2025
IDH1
|
IDH1 R132H • IDH1 R132
|
temozolomide • Stivarga (regorafenib)
Phase 1/2
Sidney Kimmel Comprehensive Cancer Center at Jo...
Completed
Last update posted :
02/09/2024
Initiation :
01/03/2020
Primary completion :
10/31/2023
Completion :
10/31/2023
IDH1 • IDH2
|
IDH1 R132 • IDH2 R140 • IDH2 R172
|
temozolomide • Partruvix (pamiparib)
Phase 1/2
Washington University School of Medicine
Recruiting
Last update posted :
01/12/2024
Initiation :
01/04/2019
Primary completion :
01/31/2032
Completion :
01/31/2032
IDH1 • MGMT
|
IDH1 R132H • IDH wild-type • IDH1 R132
|
temozolomide • Hyleukin-7 (efineptakin alfa)
Phase 3
NRG Oncology
Recruiting
Last update posted :
01/10/2024
Initiation :
11/29/2021
Primary completion :
08/08/2026
Completion :
08/08/2031
IDH1 • MGMT
|
MGMT promoter methylation • IDH1 R132H • IDH1 R132
|
temozolomide • lomustine
Phase 2
Daiichi Sankyo Co., Ltd.
Active, not recruiting
Last update posted :
12/11/2023
Initiation :
07/08/2020
Primary completion :
03/10/2023
Completion :
06/30/2026
IDH1
|
IDH1 mutation • IDH1 R132
|
safusidenib (AB-218)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
12/06/2023
Initiation :
08/04/2020
Primary completion :
12/01/2024
Completion :
12/01/2024
IDH1 • IDH2
|
IDH2 mutation • IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH wild-type • IDH1 R132 • IDH1 R132G • IDH2 R140Q • IDH1 R132L • IDH1 R132S • IDH1 R132V • IDH2 R172 • IDH2 R172G
|
Lynparza (olaparib)
Phase 3
Institut de Recherches Internationales Servier
Active, not recruiting
Last update posted :
12/05/2023
Initiation :
01/05/2020
Primary completion :
09/06/2022
Completion :
08/01/2027
IDH1 • IDH2
|
IDH2 mutation • IDH1 R132H • IDH2 R172K • IDH1 R132 • IDH2 R172
|
vorasidenib (S95032)
Phase 2
Jason J. Luke, MD
Completed
Last update posted :
12/01/2023
Initiation :
09/20/2021
Primary completion :
11/13/2023
Completion :
11/13/2023
IDH1
|
IDH1 R132C • IDH1 R132
|
Opdivo (nivolumab) • Tibsovo (ivosidenib)
Phase 1/2
Forma Therapeutics, Inc.
Completed
Last update posted :
11/20/2023
Initiation :
11/01/2018
Primary completion :
05/24/2021
Completion :
06/13/2022
IDH1
|
IDH1 R132
|
Opdivo (nivolumab) • cisplatin • gemcitabine • azacitidine • Rezlidhia (olutasidenib)
Phase 3
Servier Affaires Médicales
Recruiting
Last update posted :
11/20/2023
Initiation :
06/14/2023
Primary completion :
01/01/2026
Completion :
12/15/2026
IDH1
|
IDH1 R132
|
Tibsovo (ivosidenib)
Phase 1/2
Northwestern University
Recruiting
Last update posted :
11/15/2023
Initiation :
10/29/2020
Primary completion :
09/10/2024
Completion :
09/01/2025
IDH1 • SSR3
|
IDH1 R132H • IDH wild-type • IDH1 R132
|
carboplatin • albumin-bound paclitaxel
Phase 2
AnHeart Therapeutics Inc.
Recruiting
Last update posted :
11/14/2023
Initiation :
06/05/2023
Primary completion :
03/31/2027
Completion :
07/31/2027
IDH1
|
IDH1 R132H • IDH1 R132C • IDH1 R132
|
LY3295668 • safusidenib (AB-218)
Phase 1
Eli Lilly and Company
Active, not recruiting
Last update posted :
09/01/2023
Initiation :
12/01/2020
Primary completion :
07/03/2023
Completion :
05/01/2024
IDH1 • IDH2
|
IDH2 mutation • IDH1 R132 • IDH2 R140 • IDH2 R172
|
Venclexta (venetoclax) • azacitidine • LY3410738
Phase 1
Eli Lilly and Company
Active, not recruiting
Last update posted :
09/01/2023
Initiation :
10/16/2020
Primary completion :
07/17/2023
Completion :
05/01/2024
IDH1 • IDH2
|
IDH2 mutation • IDH1 R132 • IDH2 R140 • IDH2 R172
|
cisplatin • Imfinzi (durvalumab) • gemcitabine • LY3410738
Phase 2
Patrick Wen, MD
Recruiting
Last update posted :
08/09/2023
Initiation :
02/09/2017
Primary completion :
03/01/2025
Completion :
12/31/2025
IDH1
|
IDH1 R132H • IDH1 R132
|
temozolomide • Nerlynx (neratinib) • Verzenio (abemaciclib) • CC-115 • QBS72S
Phase 1
Dana-Farber Cancer Institute
Recruiting
Last update posted :
08/08/2023
Initiation :
07/18/2017
Primary completion :
12/01/2024
Completion :
12/01/2025
IDH1
|
IDH1 mutation • IDH1 R132H • IDH wild-type • IDH1 R132
|
cyclophosphamide • CAN-3110
Phase 2
European Organisation for Research and Treatmen...
Withdrawn
Last update posted :
05/24/2023
Initiation :
09/13/2022
Primary completion :
12/19/2022
Completion :
12/19/2022
IDH1 • MGMT
|
MGMT promoter methylation • IDH1 R132H • IDH1 R132
|
lomustine • Nplate (romiplostim)
Phase 1
Northwestern University
Recruiting
Last update posted :
05/15/2023
Initiation :
12/21/2020
Primary completion :
12/01/2026
Completion :
12/01/2028
IDH1 • UGT1A1
|
IDH1 R132 • UGT1A1*1*1 • UGT1A1 mutation
|
cytarabine • Tibsovo (ivosidenib) • fludarabine IV • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)
Phase 1
CStone Pharmaceuticals
Completed
Last update posted :
02/13/2023
Initiation :
11/12/2019
Primary completion :
02/18/2021
Completion :
01/18/2023
IDH1
|
IDH1 R132
|
Tibsovo (ivosidenib)
Phase 3
Institut de Recherches Internationales Servier
Completed
Last update posted :
01/16/2023
Initiation :
02/20/2017
Primary completion :
01/31/2019
Completion :
05/17/2021
IDH1
|
IDH1 R132C • IDH1 R132
|
Tibsovo (ivosidenib)
Phase 1
German Cancer Research Center
Recruiting
Last update posted :
12/21/2022
Initiation :
10/19/2018
Primary completion :
09/01/2023
Completion :
09/01/2024
IDH1 • ATRX
|
IDH1 R132
|
Bavencio (avelumab) • IDH1R132H peptide vaccine
Phase 1b
City of Hope Medical Center
Withdrawn
Last update posted :
06/09/2022
Initiation :
06/25/2022
Primary completion :
12/15/2023
Completion :
12/15/2023
FLT3 • ABL1 • BCR • IDH1 • AXL
|
IDH1 mutation • BCR-ABL1 fusion • FLT3 mutation • FLT3 D835 • IDH1 R132 • FLT3 I836
|
Venclexta (venetoclax) • Xospata (gilteritinib) • azacitidine • Bosulif (bosutinib) • decitabine • Tibsovo (ivosidenib) • Idhifa (enasidenib) • Daurismo (glasdegib)